Press release | 05.12.17

Assystem acquiring a controlling interest in The Biotech Quality Group

Assystem S.A. announced that is has acquired a 72.7% interest in the Belgian consulting firm, The Biotech Quality Group (BQG), which specializes in performance management and improving regulatory compliance within Europe’s pharmaceutical and biotech industries.

BQG currently employs some 100 people and generates a total of €11 million in annual revenue across Belgium, France and Switzerland. Since it was founded in 2011 it has developed a range of bespoke methods and tools aimed at increasing the maturity and transforming the practices of the (bio)pharmaceutical industry, reducing time to market and production stoppages, and effectively managing and remedying crisis situations. BQG provides its clients with the necessary expertise to ensure that their projects meet the highest standards in terms of compliance, quality and performance.

BQG’s skills and client portfolio form an excellent strategic fit with those of Assystem in the Life Sciences sector. Through its Energy & Infrastructure division (“Assystem E&I”), Assystem is specialised in the operational aspects of commissioning, certifying and validating drug and biopharmaceutical production lines allowing manufacturers to comply with regulatory requirements, including the most stringent of them.

The combined skills and expertise of BQG and Assystem will enable us to propose to the market a unique offering encompassing quality, regulatory compliance and performance at all stages of a drug’s life cycle, from the creation phase right up until it is introduced on the market.

As a result of the acquisition of BQG, the number of Assystem’s engineers, pharmacists and academics specialized in certification, validation and regulatory compliance in the pharmaceutical and biotech industries in Europe has increased to nearly 400. The merged outfit is expected to generate an estimated €40 million in revenue in 2018.

Through this move, Assystem has taken another major step forward in implementing its Life Sciences strategy, which is aimed at making the Group a European leader in the areas of commissioning, certification, validation and regulatory compliance in the pharmaceutical and biotech industries in Europe and at further developing its Life Sciences engineering activities.

After carrying out the requisite consultation processes with employee representatives, in order to leverage commercial, technical and organisational synergies between BQG’s activities and Assystem’s existing operations in the Life Sciences sector, it is planned that all of BQG’s and Assystem’s Life Sciences operations will be brought together into a single entity.

The Chairman, CEO and COO of the combined entity will be, respectively, Thomas Branche, Senior Vice President Energy Transition & Infrastructures of Assystem E&I, Fabrice Dekoninck, BQG’s current CEO, and Laurent Hackenberger, the current Director of Assystem E&I’s Life Sciences operations.

Related news

Press release 02.06.20

Assystem acquires Corporate Risk Associates

News 01.06.20

Assystem announces two collaborations on fusion experiments with UK and with China

Press release 06.05.20

Assystem secures contract on UK Ministry of Defence nuclear framework

News 29.04.20

SMR consortium appoints new interim CEO